Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 9/20 | 0.65 |
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281308 | 1.00 | ALDH1A1 (0.80) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL351439 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30281223 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15789002 | 0.86 | ALDH1A1 (0.94) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20794324 | 0.86 | ALDH1A1 (0.78) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2645698 | 0.86 | ALDH1A1 (0.78) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2644980 | 0.84 | ALDH1A1 (0.74) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8243731 | 0.83 | ALDH1A1 (0.78) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL743304 | 0.82 | MEN1 (1.00) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15568236 | 0.82 | ALDH1A1 (0.72) | ALDH1A1HPGDCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | TEXAS CROP SCIENCE, INC. | 2024-03-28 | — | — | US | claimed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | claimed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | claimed |
| CN-102971291-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2013-03-13 | — | — | CN | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101541801-A | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-09-23 | — | — | CN | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1940835-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-09 | — | — | EP | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007036733-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1806/4885HPGD 313/4885CYP1A2 763/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | ALDH1A1 1806/4885HPGD 313/4885CYP1A2 763/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | ALDH1A1 3102/4885HPGD 2131/4885CYP1A2 2757/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1806/4885HPGD 313/4885CYP1A2 763/4885 |
| US-20240099300-A1 | SULFONAMIDE APYRASE INHIBITORS | APEH, ARSA, DNPEP | ALDH1A1 1085/4885HPGD 1285/4885CYP1A2 522/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1806/4885HPGD 313/4885CYP1A2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.